Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies Chapter 37

Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies Chapter 37
复制标题

实验和人类帕金森病的补偿机制:新疗法的潜力第 37 章

DOI:
--
复制
发表时间:
2010
期刊:
影响因子:
--
通讯作者:
J. Obeso
J. Obeso
中科院分区:
--
文献类型:
--
作者:
E. Bézard;G. Porras;J. Blesa;J. Obeso

文献摘要

参考文献

被引文献

相似文献

帕金森病(PD)是一种广泛存在的神经退行性疾病,其主要病理特征是色素多巴胺(DA)神经元的严重丧失,主要发生在黑质致密部(SNc)(Hassler,1938;Ehringer和Hornykiewicz,1960)(另见第34章)。 PD 的主要特征,即震颤、僵硬和运动迟缓(Singh 等,2007),通常在 DA 神经元死亡达到临界阈值时出现:纹状体神经末梢 70-80% 和 SNc perikarya 50-60%(Bernheimer 等,1973)。帕金森运动特征的出现与 DA 大量消耗之间的这种分离被理解为补偿机制的结果(Zigmond 等,1990;Bezard 和 Gross,1998;Bezard 等,2003)。因此,代偿机制可以延迟帕金森病的临床发作,也可能在运动缺陷的进展中发挥作用。确实,补偿的可能性很大
Parkinson’s disease (PD) is a widespread neurodegen-erative disorder, the major pathologic feature of which is the profound loss of pigmented dopamine (DA) neu-rons, mainly in the pars compacta of the substantia nigra (SNc) (Hassler, 1938; Ehringer and Hornykiewicz, 1960) (see also Chapter 34). The cardinal features of PD, that is, tremor, rigidity and bradykinesia (Singh et al., 2007), typically arise when DA neuronal death reaches a critical threshold: 70–80% of striatal nerve terminals and 50–60% of SNc perikarya (Bernheimer et al., 1973). This dissocia-tion between the onset of parkinsonian motor features and the presence of large DA depletions is understood as a con-sequence of compensatory mechanisms (Zigmond et al., 1990; Bezard and Gross, 1998; Bezard et al., 2003). Thus, compensatory mechanisms can delay the clinical onset of PD and could also play a role in the progression of motor deficits. Indeed, it is quite possible that compensatory
DOI: 10.1073/pnas.0409766102
发表时间: 2005-03-01
影响因子: 11.1
作者:
Seeman, P;Weinshenker, D;Tallerico, T
通讯作者: Tallerico, T
DOI: 10.1093/brain/awm086
发表时间: 2007-07-01
期刊: BRAIN
影响因子: 14.5
作者:
Huang, Chaorui;Tang, Chengke;Eidelberg, David
通讯作者: Eidelberg, David
脑内 6-羟基多巴胺后从纹状体切片中流出的多巴胺:残余末梢代偿性亢进的证据。
DOI: --
发表时间: 1990
期刊: The Journal of pharmacology and experimental therapeutics
影响因子: --
作者:
Snyder,GL;KellerJr,RW;Zigmond,MJ
通讯作者: Zigmond,MJ